Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$143.45
pos +0.00
+0.00%
Today's Range: 141.00 - 144.58 | AMGN Avg Daily Volume: 3,889,600
Last Update: 12/09/16 - 4:00 PM EST
Volume: 0
YTD Performance: -11.63%
Open: $0.00
Previous Close: $140.59
52 Week Range: $133.64 - $176.85
Oustanding Shares: 743,922,473
Market Cap: 104,588,060,479
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 1 1 1 1
Hold 11 11 11 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.41 2.41 2.41 2.37
Latest Dividend: 1.00
Latest Dividend Yield: 2.85%
Dividend Ex-Date: 11/14/16
Price Earnings Ratio: 12.43
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
12.43 14.90 31.10
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-13.87% -9.15% 25.86%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.00 0.20 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.60 0.18
Earnings for AMGN:
EBITDA 10.63B
Revenue 21.66B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $2.78 $2.89 $11.53 $12.30
Number of Analysts 11 6 13 13
High Estimate $2.89 $3.03 $11.65 $14.03
Low Estimate $2.63 $2.77 $11.39 $11.47
Prior Year $2.61 $2.90 $10.38 $11.53
Growth Rate (Year over Year) 6.34% -0.34% 11.11% 6.61%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
If the market is going to overreact to every new missive from Trump, I plan to take advantage.
Check out these 15 stocks that boast solid dividend yields and are growing earnings.
But we could see more volatility in the market.
I continue to believe downside risks far outweigh the risks of a near-term rally.
We may see a respite of the recent pressure for a few days, but it can't be trusted to last.
AMGN is neutral now, but a close below $158 weakens the chart picture.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
The once-mighty biotech has fallen, but entry opportunities will surface.
The shares have some power and legs to get up and through old highs.

Columnist Conversations

From The Restaurant Finance Monitor... http://www.restfinance.com/Restaurant-Finance-Across-America/Decem...
This week's biggest gainer in the S&P 500 was Borg Warner.  The auto parts maker surged over 15% with...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.